Back to Results
First PageMeta Content
Health / Biology / Russian Venture Company / Tuberculosis treatment / Extensively drug-resistant tuberculosis / Multi-drug-resistant tuberculosis / Skolkovo Foundation / Skolkovo innovation center / Tuberculosis / Antibiotic-resistant bacteria / Medicine


PRESS RELEASE 19 December 2012, Moscow and Rockville, MD, USA Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of S
Add to Reading List

Document Date: 2012-12-19 07:40:08

Open Document

File Size: 110,69 KB

Share Result on Facebook

City

Moscow / Rockville / Boston / /

Company

IBM / Johnson & Johnson / Sequella Infectex / Cowen and Company / Infectex Ltd. / Cisco Systems / Nokia / EADS / GE / Russian Venture Company / Maxwell Biotech Venture Fund’s Portfolio Company / Boeing / Intel / Microsoft / Siemens / Sequella Inc. / Maxwell Biotech Group / /

Continent

Africa / /

Country

Russia / United States / /

Currency

RUB / USD / /

/

Event

FDA Phase / Funding / Business Partnership / /

Facility

Skolkovo Institute of Technology / National Institute of Allergy / Skolkovo Innovation Center / Massachusetts Institute of Technology / /

IndustryTerm

technology innovation / biotechnology / stage pharmaceutical / /

MedicalCondition

TB / TB disease / TB infection / Enrolls First Multi-Drug Resistant Tuberculosis / cardiovascular diseases / XDR-TB / multidrug-resistant tuberculosis / metabolic diseases / resistant infectious diseases / Helicobacter pylori infections / liver diseases / inflammatory respiratory diseases / bone diseases / infectious disease / /

MedicalTreatment

antibiotics / chemotherapy / /

Organization

Russian government / Maxwell Biotech Venture Fund Maxwell Biotech Venture Fund / National Institute of Health / World Health Organization / Skolkovo Innovation Centre / Massachusetts Institute of Technology / Skolkovo Foundation / National Institute of Allergy and Infectious Diseases / Institute of Technology / Skolkovo Innovation Center / USA Maxwell Biotech Venture Fund / /

Person

Oksana Markova / Leonid Gankin / Carol Nacy / Alan S. Klein / Alexey Eliseev / /

/

Position

CEO / Managing Director / Vice President / Corporate Development / Executive Vice President / Corporate Development / /

Product

isoniazid / SQ109 / Texas / /

ProvinceOrState

Texas / Indiana / Massachusetts / /

Technology

combinatorial chemistry / biotechnology / lasers / chemotherapy / /

URL

http /

SocialTag